A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study).

MLA

Shoichi Hazama, et al. “A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study).” Clinical Colorectal Cancer, vol. 15, no. 4, Dec. 2016, pp. 329–36. EBSCOhost, https://doi.org/10.1016/j.clcc.2016.07.003.

APA

Shoichi Hazama, Hiromichi Maeda, Shigeyoshi Iwamoto, Ho Min Kim, Hiroyoshi Takemoto, Kenji Kobayashi, Junichi Sakamoto, Naoki Nagata, Koji Oba, Hideyuki Mishima, Hazama, S., Maeda, H., Iwamoto, S., Kim, H. M., Takemoto, H., Kobayashi, K., Sakamoto, J., Nagata, N., Oba, K., & Mishima, H. (2016). A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study). Clinical Colorectal Cancer, 15(4), 329–336. https://doi.org/10.1016/j.clcc.2016.07.003

Chicago

Shoichi Hazama, Hiromichi Maeda, Shigeyoshi Iwamoto, Ho Min Kim, Hiroyoshi Takemoto, Kenji Kobayashi, Junichi Sakamoto, et al. 2016. “A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study).” Clinical Colorectal Cancer 15 (4): 329–36. doi:10.1016/j.clcc.2016.07.003.